name: Upper extremity addition, external powered feature, myoelectronic control module, additional emg inputs, pattern-recognition decoding intent movement


name: Addition to upper extremity, user adjustable, mechanical, residual limb volume management system


name: Air polymer-type a intrauterine foam, per study dose


name: Infectious disease (acid-fast bacteria and invasive fungi), dna (673 organisms), nextgeneration sequencing, plasm


name: Rare diseases (constitutional disease/hereditary disorders), rapid whole genome and mitochondrial dna sequencing for singlenucleotide variants, insertions/deletions, copy number variations, peripheral blood, buffy coat, saliva, buccal or tissue sample, results reported as positive or negative


name: Drug metabolism (adverse drug reactions and drug response), genotyping of 16 genes (ie, abcg2, cyp2b6, cyp2c9, cyp2c19, cyp2c, cyp2d6, cyp3a5, cyp4f2, dpyd, g6pd, ggcx, nudt15, slco1b1, tpmt, ugt1a1, vkorc1), reported as metabolizer status and transporter function


name: Oncology (prostate), microrna, single-nucleotide polymorphisms (snps) analysis by rt-pcr of 32 variants, using buccal swab algorithm reported as a risk score


name: Perfluoroalkyl substances (pfas) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), by liquid chromatography with tandem mass spectrometry (lcms/ms), plasma or serum, quantitative


name: Red blood cell antigen (fetal rhd), pcr analysis of exon 4 of rhd gene and housekeeping control gene gapdh from whole blood in pregnant individuals at 10+ weeks gestation known to be rhd negative, reported as fetal rhd status


name: Oncology (colorectal cancer), analysis of cell-free dna for epigenomic patterns, nextgeneration sequencing, >2500 differentially methylated regions (dmrs), plasma, algorithm reported as positive or negative


name: Oncology (solid tumor), nextgeneration targeted sequencing analysis, formalin-fixed paraffinembedded (ffpe) tumor tissue, dna analysis of 600 genes, interrogation for single-nucleotide variants, insertions/deletions, gene rearrangements, and copy number alterations, microsatellite instability, tumor mutation burden, reported as actionable variant


name: Oncology (solid tumor), cellfree circulating tumor dna (ctdna), 152 genes, nextgeneration sequencing, interrogation for singlenucleotide variants, insertions/deletions, gene rearrangements, copy number alterations, and microsatellite instability, using whole-blood samples, mutations with clinical actionability reported as actionable variant


name: Transplantation medicine, quantification of donorderived cell-free dna using next-generation sequencing analysis of plasma, reported as percentage of donorderived cell-free dna to determine probability of rejection


name: Cardiovascular disease (hdl reverse cholesterol transport), cholesterol efflux capacity, lc-ms/ms, quantitative measurement of 5 distinct hdl-bound apolipoproteins (apolipoproteins a1, c1, c2, c3, and c4), serum, algorithm reported as prediction of coronary artery disease (pcad) score


name: Nephrology (renal transplant), urine, nuclear magnetic resonance (nmr) spectroscopy measurement of 84 urinary metabolites, combined with patient data, quantification of bk virus (human polyomavirus 1) using real-time pcr and serum creatinine, algorithm reported as a probability score for allograft injury status


name: Oncology (solid tumor), nextgeneration sequencing of dna from formalin-fixed paraffin-embedded (ffpe) tissue of 517 genes, interrogation for single- nucleotide variants, multinucleotide variants, insertions and deletions from dna, fusions in 24 genes and splice variants in 1 gene from rna, and tumor mutation burden


name: Nephrology (transplant monitoring), 48 variants by digital pcr, using cell-free dna from plasma, donor-derived cell-free dna, percentage reported as risk for rejection


name: Acetylcholine receptor (achr), antibody identification by immunofluorescence, using live cells, reported as positive or negative


name: Low-density lipoprotein receptor-related protein 4 (lrp4), antibody identification by immunofluorescence, using live cells, reported as positive or negative


name: Neurofilament light chain (nfl), chemiluminescent enzyme immunoassay, plasma, quantitative


name: Glial fibrillary acidic protein (gfap), chemiluminescent enzyme immunoassay, using plasma


name: Oncology (urothelial), dna, quantitative methylated realtime pcr of trna-cys, sim2, and nkx1-1, using urine, diagnostic algorithm reported as a probability index for bladder cancer and/or upper tract urothelial carcinoma (utuc)


name: Oncology (prostate), enzymelinked immunosorbent assays (elisa) for total prostatespecific antigen (psa) and free psa, serum, combined with age, previous negative prostate biopsy status, digital rectal examination findings, prostate volume, and image and data reporting of the prostate, algorithm reported as a risk score for the presence of high-grade prostate cancer


name: Tau, phosphorylated, ptau217, by single-molecule array (ultrasensitive digital protein detection), using plasma


name: Management of stereotactic body radiation therapy for cranial lesion(s) over 1-5 sessions


name: Established patient office or other outpatient visit with low level of decision making, if using time, 20 minutes or more


name: Subsequent hospital inpatient or observation care with moderate level of medical decision making, if using time, 35 minutes or more


name: SNOMEDCT_US_2025_03_01 to ICD10_2016 Mappings


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version Clinical Classification


name: Medication Reference Terminology, 2025_03_03


name: Autologous Genome-Edited Hematopoietic Stem-Cell-Based Gene Therapy [EPC]


name: Oligonucleotide Telomerase Inhibitor [EPC]


name: Melanoma-associated Antigen A4-directed Genetically Modified Autologous T Cell Immunotherapy [EPC]


name: Thyroid Hormone Receptor beta Agonist [EPC]


name: Peroxisome Proliferator-activated Receptor Agonist [EPC]


name: Peroxisome Proliferator Receptor delta Agonist [EPC]


name: CXC Chemokine Receptor 4 Antagonist [EPC]


name: Interleukin-31 Receptor alpha Antagonist [EPC]


name: Colony Stimulating Factor-1 Receptor Blocker [EPC]


name: Czech translation of the Medical Subject Headings, 2025